066700 — THERAGEN ETEX CO Share Price
Last trade - 00:00- KR₩112bn
- KR₩148bn
- KR₩222bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.69 | ||
| Price to Tang. Book | 0.72 | ||
| Price to Free Cashflow | 79.05 | ||
| Price to Sales | 0.46 | ||
| EV to EBITDA | 7.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.95% | ||
| Return on Equity | 18.24% | ||
| Operating Margin | 5.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 138,083.45 | 143,022.53 | 166,566.62 | 190,769.02 | 221,724.62 | n/a | n/a | 13.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +245.05 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
THERAGEN ETEX CO.LTD. is a Korea-based company engaged in the industrial equipment business, healthcare and genome business and pharmaceutical business. The Company operates its business through three divisions: flat panel display (FPD) manufacturing equipment division, which provides loading and unloading systems, printed circuit board (PCB) bonding systems, battery washing lines and laser systems; healthcare and genome division engages in the provision of genome analysis services and others, and pharmaceutical division engages in the manufacture of digestive system remedies, antibiotics, remedies for fever, circulatory system remedies, respiration system remedies, treatment for chronic hepatitis, diabetes remedies, psychotropic agents, osteoporosis treatments and others.
Directors
- Sang Gyu Kim PRE (63)
- Jin Eop Goh CCE (65)
- Tae Sun Hwang CCE (48)
- Byeong Hwan Ryu CCE (58)
- Seong Jin Kim CTO (59)
- Byeong Ha Kim VPR (53)
- Jae Hyeon Gwon VPR (38)
- Seok Hong Kang VPR (59)
- Yik Hwan Jeon MDR (52)
- Yeong Gwi Jin OTH (51)
- Seong Hui Lee OTH (43)
- Yun Bae Son OTH (54)
- Su Yeong Woo OTH (55)
- Jong Hwa Park DRC (46)
- Wuk Je Cho NID (66)
- Geon Sik Choi NID (67)
- Yeong Geun Gwon NID (49)
- Tae Seong Park NID (51)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 27th, 1990
- Public Since
- May 27th, 2004
- No. of Shareholders
- 22,214
- No. of Employees
- 252
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 32,005,379
- Address
- 58, Sandan-ro 68beon-gil, Danwon-gu, ANSAN, 15438
- Web
- https://www.theragenetex.com/
- Phone
- +82 234637111
- Auditors
- BDO Sunghyun LLC
Upcoming Events for 066700
Similar to 066700
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 23:40 UTC, shares in THERAGEN ETEX CO are trading at KR₩3,495. This share price information is delayed by 15 minutes.
Shares in THERAGEN ETEX CO last closed at KR₩3,495 and the price had moved by -15.6% over the past 365 days. In terms of relative price strength the THERAGEN ETEX CO share price has underperformed the FTSE Developed Asia Pacific Index by -28.58% over the past year.
There is no consensus recommendation for this security.
Find out moreTHERAGEN ETEX CO does not currently pay a dividend.
THERAGEN ETEX CO does not currently pay a dividend.
THERAGEN ETEX CO does not currently pay a dividend.
To buy shares in THERAGEN ETEX CO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩3,495, shares in THERAGEN ETEX CO had a market capitalisation of KR₩112bn.
Here are the trading details for THERAGEN ETEX CO:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 066700
Based on an overall assessment of its quality, value and momentum THERAGEN ETEX CO is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like THERAGEN ETEX CO. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -18.44%.
As of the last closing price of KR₩3,495, shares in THERAGEN ETEX CO were trading -12.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The THERAGEN ETEX CO PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩3,495.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
THERAGEN ETEX CO's management team is headed by:
- Sang Gyu Kim - PRE
- Jin Eop Goh - CCE
- Tae Sun Hwang - CCE
- Byeong Hwan Ryu - CCE
- Seong Jin Kim - CTO
- Byeong Ha Kim - VPR
- Jae Hyeon Gwon - VPR
- Seok Hong Kang - VPR
- Yik Hwan Jeon - MDR
- Yeong Gwi Jin - OTH
- Seong Hui Lee - OTH
- Yun Bae Son - OTH
- Su Yeong Woo - OTH
- Jong Hwa Park - DRC
- Wuk Je Cho - NID
- Geon Sik Choi - NID
- Yeong Geun Gwon - NID
- Tae Seong Park - NID